- Navidea Biopharmaceuticals (NAVB) jumps 30% in premarket trading.
- The company says the FDA has granted a Fast Track designation to Lymphoseek for "sentinel lymph node detection in patients with head and neck cancer."
- The radiopharmaceutical is currently approved for use in helping to diagnose the spread of breast cancer and melanoma.
- NAVB says it expects to file an sNDA "before year-end." (PR)
Navidea Bio soars on Fast Track designation for Lymphoseek
Dec 10 2013, 07:57 ET